

**decapeptyl™ SR 11.25mg (Triptorelin acetate) (No. 109/04)**

**Ipsen Ltd**

**Product Update**

12 July 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE:** following an abbreviated submission

Decapeptyl™ SR 11.25mg is accepted for use within NHS Scotland for the treatment of advanced prostate cancer in patients for whom the use of triptorelin is appropriate and who would benefit from reduced frequency of administration compared with Decapeptyl™ SR 3mg (every 3 months vs every 28 days).

**Professor D H Lawson**  
**Chairman**